Trial Profile
A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma Related Bone Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Bone disorders; Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 02 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Jul 2012 Planned number of patients changed from 100 to 120 as reported by European Clinical Trials Database.